What can we learn about valvular heart disease from PET/CT?

Future Cardiology

Volumn 9, Issue 5, 2013, Pages 657-667

  Jenkins, William S A ^a   Chin, Calvin ^a,b   Rudd, James H F ^c   Newby, David E ^a   Dweck, Marc R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Singapore Health Services   (Singapore)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Aortic stenosis; Cardiac imaging; Infective endocarditis; PET; PET CT; Valvular heart disease

Indexed keywords

DOTATATE GA 68; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; NAF F 18; PBR28 C 11; SODIUM FLUORIDE F 18; TRACER; UNCLASSIFIED DRUG;

ANGIOGENESIS; AORTA STENOSIS; APOPTOSIS; BACTERIAL ENDOCARDITIS; CALCIFICATION; CARDIOVASCULAR RISK; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEART MUSCLE FIBROSIS; HUMAN; INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; VALVULAR HEART DISEASE;

DIAGNOSIS, DIFFERENTIAL; HEART VALVE DISEASES; HUMANS; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84884165771     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.47     Document Type: Review

References (79)

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 368(9540), 1005-1011 (2006).
2. Dweck MR, Jones C, Joshi NV et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 125(1), 76-86 (2012).
3. Millar BC, Prendergast BD, Alavi A, Moore JE. 18FDG-positron emission tomography (PET) has a role to play in the diagnosis and therapy of infective endocarditis and cardiac device infection. Int. J. Cardiol. pii: S0167-S5273(12), 01633-01636 (2013).
4. Rudd JHF, Myers KS, Bansilal S et al. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible. J. Am. Coll. Cardiol. 50(9), 892-896 (2007).
5. van den Borne SWM, Isobe S, Verjans JW et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J. Am. Coll. Cardiol. 52(24), 2017-2028 (2008).
6. Gaemperli O, Kaufmann PA. PET and PET/CT in cardiovascular disease. Ann. NY Acad. Sci. 1228(1), 109-136 (2011).
7. Pichler BJ, Wehrl HF, Judenhofer MS. Latest advances in molecular imaging instrumentation. J. Nucl. Med. 49(Suppl. 2), S5-S23 (2008).
8. Berman DS, Germano G, Slomka PJ. Improvement in PET myocardial perfusion image quality and quantification with flurpiridaz F 18. J. Nucl. Cardiol. 19(Suppl. 1), S38-S45 (2012).
9. Woo J, Tamarappoo B, Dey D et al. Automatic 3D registration of dynamic stress and rest 82Rb and flurpiridaz F 18 myocardial perfusion PET data for patient motion detection and correction. Med. Phys. 38(11), 6313 (2011).
10. Kaneko K, Kawasaki T, Masunari S, Yoshida T, Omagari J. Determinants of extraaortic arterial 18F-FDG accumulation in asymptomatic cohorts: sex differences in the association with cardiovascular risk factors and coronary artery stenosis. J. Nucl. Med. 54(4), 564-570 (2013).
11. Rudd JH, Warburton EA, Fryer TD et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105(23), 2708-2711 (2002).
12. Tawakol A, Migrino RQ, Bashian GG et al. In vivo 18F fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol. 48(9), 1818-1824 (2006).
13. Saam T, Rominger A, Wolpers S et al. Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: a PET/CT study. Eur. J. Nucl. Med. Mol. Imaging 37(6), 1203-1212 (2010).
14. Marnane M, Merwick A, Sheehan OC et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann. Neurol. 71(5), 709-718 (2012).
15. Paulmier B, Duet M, Khayat R et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J. Nucl. Cardiol. 15(2), 209-217 (2008).
16. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis. J. Am. Coll. Cardiol. 60(19), 1854-1863 (2012).
17. Marincheva-Savcheva G, Subramanian S, Qadir S et al. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol. 57(25), 2507-2515 (2011).
18. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. Am. J. Roentgenol. 190(2), W151-W156 (2008).
19. Cook GJ, Blake GM, Marsden PK, Cronin B, Fogelman I. Quantification of skeletal kinetic indices in paget's disease using dynamic 18F-fluoride positron emission tomography. J. Bone Miner. Res. 17(5), 854-859 (2002).
20. Frost ML, Fogelman I, Blake GM, Marsden PK, Cook G. Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J. Bone Miner. Res. 19(11), 1797-1804 (2004).
21. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J. Nucl. Med. 49(1), 68-78 (2008).
22. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circulation Res. 89(12), 1147-1154 (2001).
23. Kaden JJ, Bickelhaupt S, Grobholz R et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J. Mol. Cell. Cardiol. 36(1), 57-66 (2004).
24. Kaden JJ, Kiliç R, Sarikoç A et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. Int. J. Mol. Med. 16(5), 869-872 (2005).
25. Steiner I, Kasparová P, Kohout A, Dominik J. Bone formation in cardiac valves: a histopathological study of 128 cases. Virchows Arch. 450(6), 653-657 (2007).
26. Cowell SJ, Newby DE, Burton J et al. Aortic valve calcification on computed tomography predicts the severity of aortic stenosis. Clin. Radiol. 58(9), 5 (2003).
27. Davies SW, Gershlick AH, Balcon RR. Progression of valvar aortic stenosis: a long-term retrospective study. Eur. Heart J. 12(1), 10-14 (1991).
28. Rosenhek RR, Binder TT, Porenta GG et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N. Engl. J. Med. 343(9), 611-617 (2000).
29. Hyafil F, Messika-Zeitoun D, Burg S et al. Detection of 18fluoride sodium accumulation by positron emission tomography in calcified stenotic aortic valves. Am. J. Cardiol. 109(8), 1194-1196 (2012).
30. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol. J. Am. Coll. Cardiol. 57(16), 1666-1675 (2011).
31. Cowell SJ, Newby DE, Robin J et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352, 2389-2397 (2005).
32. Carabello BA. The SEAS trial. Curr. Cardiol. Rep. 12(2), 122-124 (2010).
33. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 121(2), 306-314 (2010).
34. Dweck MR, Khaw HJ, Sng GKZ et al. Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur. Heart J. 34(21), 1567-1574 (2013).
35. Ben-Haim S, Gacinovic S, Israel O. Cardiovascular infection and inflammation. Semin. Nucl. Med. 39(2), 103-114 (2009).
36. Takano H, Nakagawa K, Ishio N et al. Active myocarditis in a patient with chronic active Epstein-Barr virus infection. Int. J. Cardiol. 130(1), e11-e13 (2008).
37. Treglia G, Mattoli MV, Leccisotti L, Ferraccioli G, Giordano A. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin. Rheumatol. 30(10), 1265-1275 (2011).
38. Fisk M, Peck LF, Miyagi K et al. Mycotic aneurysms: a case report, clinical review and novel imaging strategy. QJM 105(2), 181-188 (2012).
39. Marion MD, Swanson MK, Spellman J, Spieth ME. Femoropopliteal prosthetic bypass graft infection due to Mycobacterium abscessus localized by FDG-PET/CT scan. J. Vasc. Surg. 50(4), 907-909 (2009).
40. Spacek M, Belohlavek O, Votrubova J, Sebesta P, Stadler P. Diagnostics of "non-acute" vascular prosthesis infection using 18F-FDG PET/CT: our experience with 96 prostheses. Eur. J. Nucl. Med. Mol. Imaging 36(5), 850-858 (2008).
41. Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of 18F-FDG PET/CT. J. Nucl. Med. 49(12), 1980-1985 (2008).
42. van der Bruggen W. PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review. Semin. Nucl. Med. 40, 3-15 (2010).
43. Zhuang H, Yang H, Alavi A. Critical role of 18F-labeled fluorodeoxyglucose PET in the management of patients with arthroplasty. Radiol. Clin. North Am. 45(4), 711-718 (2007).
44. Durack DT, Lukes AS, Bright DK, Duke Endocarditis Service. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am. J. Med. 96(3), 200-209 (1994).
45. Yen RF, Chen YC, Wu YW, Pan MH, Chang SC. Using 18-fluoro-2-deoxyglucose positron emission tomography in detecting infectious endocarditis/endoarteritis - a preliminary report. Acad. Radiol. 11(3), 316-321 (2004).
46. Kouijzer IJ, Vos FJ, Janssen MJ, Dijk AP, Oyen WJ, Bleeker-Rovers CP. The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. Eur. J. Nucl. Med. Mol. Imaging 40(7), 1102-1107 (2013).
47. Van Riet J, Hill EE, Gheysens O et al. 18F-FDG PET/CT for early detection of embolism and metastatic infection in patients with infective endocarditis. Eur. J. Nucl. Med. Mol. Imaging 37, 1189-1197 (2010).
48. Potpara TS, Vasiljevic ZM, Vujisic-Tesic BD et al. Mitral annular calcification predicts cardiovascular morbidity and mortality in middle-aged patients with atrial fibrillation: the belgrade atrial fibrillation study. Chest 140(4), 902-910 (2011).
49. Allison MA, Cheung P, Criqui MH, Langer RD, Wright CM. Mitral and aortic annular calcification are highly associated with systemic calcified atherosclerosis. Circulation 113(6), 861-866 (2006).
50. James OG, Christensen JD, Wong TZ, Borges-Neto S, Koweek LM. Utility of FDG PET/CT in inflammatory cardiovascular disease. Radiographics 31(5), 1271-1286 (2011).
51. Camici PG, Rimoldi OE, Gaemperli O, Libby P. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur. Heart J. 33(11), 1309-1317 (2012).
52. Gaemperli O, Shalhoub J, Owen DR et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur. Heart J. 33(15), 1902-1910 (2012).
53. Kreisl WC, Fujita M, Fujimura Y et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 49(4), 2924-2932 (2010).
54. Fujimura Y, Hwang PM, Trout H 3rd et al. Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: an autoradiographic study with [3H]PK 11195. Atherosclerosis 201(1), 108-111 (2008).
55. Rominger A, Saam T, Vogl E et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J. Nucl. Med. 51(2), 193-197 (2010).
56. Alam SR, Shah ASV, Richards J et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction clinical perspective. Circ. Cardiovasc. Imaging 5(5), 559-565 (2012).
57. Nahrendorf M, Zhang H, Hembrador S et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117(3), 379-387 (2008).
58. Panizzi P, Nahrendorf M, Figueiredo JL et al. In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat. Med. 17(9), 1142-1146 (2011).
59. Lygoe KA, Norman JT, Marshall JF, Lewis MP. Alphav integrins play an important role in myofibroblast differentiation. Wound Repair Regen. 12(4), 461-470 (2004).
60. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp. Cell Res. 312(5), 651-658 (2006).
61. Antonov AS, Kolodgie FD, Munn DH, Gerrity RG. Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis. Am. J. Pathol. 165(1), 247-258 (2004).
62. Luzina IG, Todd NW, Nacu N et al. Regulation of pulmonary inflammation and fibrosis through expression of integrins avb3 and avb5 on pulmonary T lymphocytes. Arthritis Rheum. 60(5), 1530-1539 (2009).
63. Soini Y, Salo T, Satta J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum. Pathol. 34(8), 756-763 (2003).
64. Akahori H, Tsujino T, Naito Yet al. Intraleaflet haemorrhage is associated with rapid progression of degenerative aortic valve stenosis. Eur. Heart J. 32(7), 888-896 (2011).
65. Rodriguez-Porcel MM, Cai WW, Gheysens OO et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J. Nucl. Med. 49(4), 667-673 (2008).
66. Rodriguez-Porcel M. Noninvasive monitoring of myocardial angiogenesis. Curr. Cardiovasc. Imaging Rep. 2(1), 59-66 (2009).
67. Fondard O. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur. Heart J. 26(13), 1333-1341 (2005).
68. Waters EA, Chen J, Allen JS, Zhang H, Lanza GM, Wickline SA. Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J. Cardiovasc. Magn. Reson. 10(1), 43 (2008).
69. Eriksen HA, Satta J, Risteli J, Veijola M, Väre P, Soini Y. Type I and Type III collagen synthesis and composition in the valve matrix in aortic valve stenosis. Atherosclerosis 189(1), 91-98 (2006).
70. Hein S. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107(7), 984-991 (2003).
71. Dweck MR, Joshi S, Murigu T et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J. Am. Coll. Cardiol. 58(12), 1271-1279 (2011).
72. Makowski MR, Ebersberger U, Nekolla S, Schwaiger M. In vivo molecular imaging of angiogenesis, targeting v 3 integrin expression, in a patient after acute myocardial infarction. Eur. Heart J. 29(18), 2201 (2008).
73. Verjans J, Wolters S, Laufer W et al. Early molecular imaging of interstitial changes in patients after myocardial infarction: comparison with delayed contrast-enhanced magnetic resonance imaging. J. Nucl. Cardiol. 17(6), 1065-1072 (2010).
74. Fukushima K, Bravo PE, Higuchi T et al. Molecular hybrid positron emission tomography/computed tomography imaging of cardiac angiotensin II type 1 receptors. J. Am. Coll. Cardiol. 60(24), 2527-2534 (2012).
75. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148(7), 2207-2216 (1992).
76. Kietselaer BL, Reutelingsperger CP, Heidendal GAK et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N. Engl. J. Med. 350(14), 1472-1473 (2004).
77. Kietselaer BL, Reutelingsperger CP, Boersma HH et al. Noninvasive detection of programmed cell loss with 99mTc-labeled annexin A5 in heart failure. J. Nucl. Med. 48(4), 562-567 (2007).
78. Saraste A, Knuuti J. Cardiac PET, CT, and MR: what are the advantages of hybrid imaging? Curr. Cardiol. Rep. 14(1), 24-31 (2012).
79. Pibarot P, Larose É, Dumesnil J. Imaging of valvular heart disease. Can. J. Cardiol. 29(3), 337-349 (2013).